Details of the Drug

General Information of Drug (ID: DMNHTZI)

Drug Name
Protriptyline
Synonyms
Amimetilina; Impril; Maximed; Novopramine; Protriptilina; Protriptylinum; Protryptyline; Rhotrimine; Triptil; Triptyl; Vivactil; Vivactyl; Triptil hydrochloride; Normethyl EX4442; Triadapin 5; Apo-Imipramine; Apo-Trimip; Novo-Doxepin; Novo-Tripramine; Protriptilina [INN-Spanish]; Protriptyline (INN); Protriptyline [INN:BAN]; Protriptylinum [INN-Latin]; Vivactil (TN); N-Methyl-5H-dibenzo[a,d]cycloheptene-5-propanamine; N-Methyl-5H-dibenzo[a,d]cycloheptene-5-propylamine; N-Methyl-5H-dibenzo(a,d)cycloheptene-5-propylamine; N-3-(5H-Dibenzo(a,d)cyclohepten-5-yl)propyl-N-methylamine; 3-(5H-Dibenzo[a,d]cyclohepten-5-yl)-N-methyl-1-propanamine; 3-(5H-dibenzo[a,d][7]annulen-5-yl)-N-methylpropan-1-amine; 5-(3-Methylaminopropyl)-5H-Dibenzo[a,d]cycloheptene; 5-(3-Methylaminopropyl)-5H-dibenzo(a,d)cycloheptene; 5H-Dibenzo[a, d]cycloheptene-5-propanamine, N-methyl-, hydrochloride; 7-(3-Methylaminopropyl)-1,2:5,6-dibenzocycloheptatriene
Indication
Disease Entry ICD 11 Status REF
Depression 6A70-6A7Z Approved [1], [2], [3]
Therapeutic Class
Antidepressants
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 263.4
Topological Polar Surface Area (xlogp) 4.4
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 1
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability
85% of drug becomes completely available to its intended biological destination(s) [5]
Elimination
1% of drug is excreted from urine in the unchanged form [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 3.2543 micromolar/kg/day [6]
Water Solubility
The ability of drug to dissolve in water is measured as 50 mg/mL [4]
Chemical Identifiers
Formula
C19H21N
IUPAC Name
N-methyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaenyl)propan-1-amine
Canonical SMILES
CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13
InChI
InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-10,12-13,19-20H,6,11,14H2,1H3
InChIKey
BWPIARFWQZKAIA-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4976
ChEBI ID
CHEBI:8597
CAS Number
438-60-8
DrugBank ID
DB00344
TTD ID
D00MYQ
VARIDT ID
DR00486
ACDINA ID
D00567

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Norepinephrine transporter (NET) TTAWNKZ SC6A2_HUMAN Inhibitor [7]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Depression
ICD Disease Classification 6A70-6A7Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Norepinephrine transporter (NET) DTT SLC6A2 7.05E-01 7.02E-03 0.07
P-glycoprotein 1 (ABCB1) DTP P-GP 7.83E-01 4.69E-02 1.89E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Protriptyline
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Trimipramine DM1SC8M Moderate Additive anticholinergic effects by the combination of Protriptyline and Trimipramine. Depression [6A70-6A7Z] [24]
Cyclobenzaprine DM1YBRM Major Additive serotonergic effects by the combination of Protriptyline and Cyclobenzaprine. Depression [6A70-6A7Z] [25]
Imipramine DM2NUH3 Moderate Additive anticholinergic effects by the combination of Protriptyline and Imipramine. Depression [6A70-6A7Z] [24]
Fluoxetine DM3PD2C Major Decreased metabolism of Protriptyline caused by Fluoxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [26]
Nortriptyline DM4KDYJ Moderate Additive anticholinergic effects by the combination of Protriptyline and Nortriptyline. Depression [6A70-6A7Z] [24]
Vilazodone DM4LECQ Major Additive serotonergic effects by the combination of Protriptyline and Vilazodone. Depression [6A70-6A7Z] [25]
Nefazodone DM4ZS8M Major Additive serotonergic effects by the combination of Protriptyline and Nefazodone. Depression [6A70-6A7Z] [25]
Paroxetine DM5PVQE Major Decreased metabolism of Protriptyline caused by Paroxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [27]
Selegiline DM6034S Major Additive serotonergic effects by the combination of Protriptyline and Selegiline. Depression [6A70-6A7Z] [28]
Vortioxetine DM6F1PU Major Additive serotonergic effects by the combination of Protriptyline and Vortioxetine. Depression [6A70-6A7Z] [25]
Duloxetine DM9BI7M Major Additive serotonergic effects by the combination of Protriptyline and Duloxetine. Depression [6A70-6A7Z] [25]
Isocarboxazid DMAF1NB Major Additive serotonergic effects by the combination of Protriptyline and Isocarboxazid. Depression [6A70-6A7Z] [28]
Milnacipran DMBFE74 Major Additive serotonergic effects by the combination of Protriptyline and Milnacipran. Depression [6A70-6A7Z] [25]
Escitalopram DMFK9HG Major Additive serotonergic effects by the combination of Protriptyline and Escitalopram. Depression [6A70-6A7Z] [29]
Tranylcypromine DMGB5RE Major Additive serotonergic effects by the combination of Protriptyline and Tranylcypromine. Depression [6A70-6A7Z] [28]
Desvenlafaxine DMHD4PE Major Additive serotonergic effects by the combination of Protriptyline and Desvenlafaxine. Depression [6A70-6A7Z] [25]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Protriptyline and OPC-34712. Depression [6A70-6A7Z] [24]
Phenelzine DMHIDUE Major Additive serotonergic effects by the combination of Protriptyline and Phenelzine. Depression [6A70-6A7Z] [28]
Clomipramine DMINRKW Moderate Additive anticholinergic effects by the combination of Protriptyline and Clomipramine. Depression [6A70-6A7Z] [24]
Trazodone DMK1GBJ Major Additive serotonergic effects by the combination of Protriptyline and Trazodone. Depression [6A70-6A7Z] [25]
Amoxapine DMKITQE Moderate Additive anticholinergic effects by the combination of Protriptyline and Amoxapine. Depression [6A70-6A7Z] [24]
Mirtazapine DML53ZJ Major Additive serotonergic effects by the combination of Protriptyline and Mirtazapine. Depression [6A70-6A7Z] [25]
Doxepin DMPI98T Moderate Additive anticholinergic effects by the combination of Protriptyline and Doxepin. Depression [6A70-6A7Z] [24]
Maprotiline DMPWB7T Moderate Additive anticholinergic effects by the combination of Protriptyline and Maprotiline. Depression [6A70-6A7Z] [24]
⏷ Show the Full List of 24 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Protriptyline (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylene blue DMJAPE7 Major Additive serotonergic effects by the combination of Protriptyline and Methylene blue. Acquired methaemoglobinaemia [3A93] [28]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Protriptyline and Ivosidenib. Acute myeloid leukaemia [2A60] [30]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Midostaurin. Acute myeloid leukaemia [2A60] [31]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Idarubicin. Acute myeloid leukaemia [2A60] [31]
Daunorubicin DMQUSBT Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Daunorubicin. Acute myeloid leukaemia [2A60] [31]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Arn-509. Acute myeloid leukaemia [2A60] [32]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Gilteritinib. Acute myeloid leukaemia [2A60] [33]
Oliceridine DM6MDCF Moderate Additive CNS depression effects by the combination of Protriptyline and Oliceridine. Acute pain [MG31] [34]
Scopolamine DMOM8AL Moderate Additive anticholinergic effects by the combination of Protriptyline and Scopolamine. Addictive disorder [6C50-6C5Z] [24]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Protriptyline and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [35]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Protriptyline and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [35]
Tripelennamine DMZBU15 Moderate Additive anticholinergic effects by the combination of Protriptyline and Tripelennamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [24]
Memantine DMD9WSC Moderate Additive anticholinergic effects by the combination of Protriptyline and Memantine. Alzheimer disease [8A20] [24]
Galantamine DMEO794 Moderate Antagonize the effect of Protriptyline when combined with Galantamine. Alzheimer disease [8A20] [36]
Rivastigmine DMG629M Moderate Antagonize the effect of Protriptyline when combined with Rivastigmine. Alzheimer disease [8A20] [36]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Protriptyline and Metronidazole. Amoebiasis [1A36] [37]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Protriptyline and Ivabradine. Angina pectoris [BA40] [32]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Protriptyline and Bepridil. Angina pectoris [BA40] [38]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Protriptyline and Dronedarone. Angina pectoris [BA40] [31]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Protriptyline and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [39]
Buspirone DMBS632 Major Additive serotonergic effects by the combination of Protriptyline and Buspirone. Anxiety disorder [6B00-6B0Z] [25]
Hydroxyzine DMF8Y74 Moderate Additive anticholinergic effects by the combination of Protriptyline and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [24]
Promazine DMZAL7W Moderate Increased plasma concentrations of Protriptyline and Promazine due to competitive inhibition of the same metabolic pathway. Appearance/behaviour symptom [MB23] [40]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Cilostazol. Arterial occlusive disease [BD40] [31]
Voriconazole DMAOL2S Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Voriconazole. Aspergillosis [1F20] [31]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Posaconazole. Aspergillosis [1F20] [31]
Methylphenidate DM7SJD6 Moderate Decreased metabolism of Protriptyline caused by Methylphenidate. Attention deficit hyperactivity disorder [6A05] [41]
Desipramine DMT2FDC Moderate Additive anticholinergic effects by the combination of Protriptyline and Desipramine. Attention deficit hyperactivity disorder [6A05] [24]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Ofloxacin. Bacterial infection [1A00-1C4Z] [42]
Ciprofloxacin XR DM2NLS9 Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [31]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Protriptyline and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [31]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Protriptyline and Sparfloxacin. Bacterial infection [1A00-1C4Z] [42]
Linezolid DMGFPU2 Major Additive serotonergic effects by the combination of Protriptyline and Linezolid. Bacterial infection [1A00-1C4Z] [43]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Gemifloxacin. Bacterial infection [1A00-1C4Z] [42]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Norfloxacin. Bacterial infection [1A00-1C4Z] [42]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Levofloxacin. Bacterial infection [1A00-1C4Z] [42]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Lomefloxacin. Bacterial infection [1A00-1C4Z] [31]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Telithromycin. Bacterial infection [1A00-1C4Z] [31]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Retigabine. Behcet disease [4A62] [31]
Loperamide DMOJZQ9 Moderate Additive antimotility effects by the combination of Protriptyline and Loperamide. Bowel habit change [ME05] [44]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Eribulin. Breast cancer [2C60-2C6Y] [31]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Lapatinib. Breast cancer [2C60-2C6Y] [31]
Tamoxifen DMLB0EZ Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Tamoxifen. Breast cancer [2C60-2C6Y] [31]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Protriptyline and Toremifene. Breast cancer [2C60-2C6Y] [31]
Grepafloxacin DMGLX0T Major Increased risk of prolong QT interval by the combination of Protriptyline and Grepafloxacin. Bronchitis [CA20] [42]
Sotalol DML60TN Major Increased risk of prolong QT interval by the combination of Protriptyline and Sotalol. Cardiac arrhythmia [BC9Z] [31]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Protriptyline when combined with Acetylcholine. Cataract [9B10] [45]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Protriptyline and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [46]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Protriptyline and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [47]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Protriptyline and Tiotropium. Chronic obstructive pulmonary disease [CA22] [47]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Protriptyline and Revefenacin. Chronic obstructive pulmonary disease [CA22] [47]
Dihydrocodeine DMB0FWL Moderate Additive serotonergic effects by the combination of Protriptyline and Dihydrocodeine. Chronic pain [MG30] [34]
Levomilnacipran DMV26S8 Major Additive serotonergic effects by the combination of Protriptyline and Levomilnacipran. Chronic pain [MG30] [25]
Oxaliplatin DMQNWRD Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Oxaliplatin. Colorectal cancer [2B91] [31]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Protriptyline and Olopatadine. Conjunctiva disorder [9A60] [48]
Mestranol DMG3F94 Minor Decreased metabolism of Protriptyline caused by Mestranol. Contraceptive management [QA21] [49]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Halothane. Corneal disease [9A76-9A78] [31]
Alfentanil DMVO0UB Moderate Additive serotonergic effects by the combination of Protriptyline and Alfentanil. Corneal disease [9A76-9A78] [34]
Remifentanil DMZTXCH Moderate Additive serotonergic effects by the combination of Protriptyline and Remifentanil. Corneal disease [9A76-9A78] [34]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Probucol. Coronary atherosclerosis [BA80] [31]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Clofazimine. Crohn disease [DD70] [50]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Protriptyline and Mifepristone. Cushing syndrome [5A70] [31]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Protriptyline and Pasireotide. Cushing syndrome [5A70] [31]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Osilodrostat. Cushing syndrome [5A70] [32]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Protriptyline and Ethanol. Cystitis [GC00] [51]
Hyoscyamine DM804UR Moderate Additive anticholinergic effects by the combination of Protriptyline and Hyoscyamine. Digestive system disease [DE2Z] [24]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Protriptyline and Mepenzolate. Digestive system disease [DE2Z] [24]
Oxybutynine DMJPBAX Moderate Additive anticholinergic effects by the combination of Protriptyline and Oxybutynine. Discovery agent [N.A.] [24]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [31]
Meclizine DMS7T13 Moderate Additive anticholinergic effects by the combination of Protriptyline and Meclizine. Dizziness and giddiness [MB48] [24]
Trihexyphenidyl DMB19L8 Moderate Additive anticholinergic effects by the combination of Protriptyline and Trihexyphenidyl. Dystonic disorder [8A02] [24]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Deutetrabenazine. Dystonic disorder [8A02] [52]
Ingrezza DMVPLNC Moderate Additive CNS depression effects by the combination of Protriptyline and Ingrezza. Dystonic disorder [8A02] [53]
Fenfluramine DM0762O Moderate Additive serotonergic effects by the combination of Protriptyline and Fenfluramine. Epilepsy/seizure [8A61-8A6Z] [54]
Zonisamide DM0DTF7 Major Additive CNS depression effects by the combination of Protriptyline and Zonisamide. Epilepsy/seizure [8A61-8A6Z] [55]
Stiripentol DMMSDOY Moderate Decreased metabolism of Protriptyline caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [56]
Fosphenytoin DMOX3LB Moderate Decreased metabolism of Protriptyline caused by Fosphenytoin mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [57]
Diphenhydramine DMKQTBA Moderate Additive anticholinergic effects by the combination of Protriptyline and Diphenhydramine. Episodic vestibular syndrome [AB31] [24]
Solifenacin DMG592Q Moderate Additive anticholinergic effects by the combination of Protriptyline and Solifenacin. Functional bladder disorder [GC50] [24]
Mirabegron DMS1GYT Moderate Decreased metabolism of Protriptyline caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [58]
Tolterodine DMSHPW8 Moderate Additive anticholinergic effects by the combination of Protriptyline and Tolterodine. Functional bladder disorder [GC50] [24]
Darifenacin DMWXLYZ Moderate Decreased metabolism of Protriptyline caused by Darifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [59]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Pentamidine. Fungal infection [1F29-1F2F] [31]
Terbinafine DMI6HUW Moderate Decreased metabolism of Protriptyline caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [60]
Ketoconazole DMPZI3Q Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Ketoconazole. Fungal infection [1F29-1F2F] [31]
Propantheline DM2EN6G Moderate Additive anticholinergic effects by the combination of Protriptyline and Propantheline. Gastric ulcer [DA60] [24]
Cimetidine DMH61ZB Moderate Decreased metabolism of Protriptyline caused by Cimetidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [61]
Cisapride DMY7PED Major Increased risk of prolong QT interval by the combination of Protriptyline and Cisapride. Gastro-oesophageal reflux disease [DA22] [31]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Sunitinib. Gastrointestinal stromal tumour [2B5B] [31]
Acetazolamide DM1AF5U Minor as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Protriptyline caused by Acetazolamide mediated altered urine pH. Glaucoma [9C61] [62]
Isoflurophate DMBSK7X Moderate Antagonize the effect of Protriptyline when combined with Isoflurophate. Glaucoma [9C61] [45]
Brimonidine DMQLT4N Moderate Additive CNS depression effects by the combination of Protriptyline and Brimonidine. Glaucoma [9C61] [63]
Pilocarpine DMV9ADG Moderate Antagonize the effect of Protriptyline when combined with Pilocarpine. Glaucoma [9C61] [45]
Carvedilol DMHTEAO Moderate Increased plasma concentrations of Protriptyline and Carvedilol due to competitive inhibition of the same metabolic pathway. Heart failure [BD10-BD1Z] [57]
Procarbazine DMIK367 Major Additive serotonergic effects by the combination of Protriptyline and Procarbazine. Hodgkin lymphoma [2B30] [28]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [64]
Cobicistat DM6L4H2 Moderate Decreased clearance of Protriptyline due to the transporter inhibition by Cobicistat. Human immunodeficiency virus disease [1C60-1C62] [65]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Protriptyline and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [66]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Protriptyline and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [67]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [31]
Atazanavir DMSYRBX Moderate Decreased metabolism of Protriptyline caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [68]
Ritonavir DMU764S Moderate Decreased metabolism of Protriptyline caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [69]
Cinacalcet DMCX0K3 Moderate Decreased metabolism of Protriptyline caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [37]
Labetalol DMK8U72 Moderate Increased plasma concentrations of Protriptyline and Labetalol due to competitive inhibition of the same metabolic pathway. Hypertension [BA00-BA04] [57]
Givosiran DM5PFIJ Moderate Decreased metabolism of Protriptyline caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [70]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Protriptyline and Belladonna. Infectious gastroenteritis/colitis [1A40] [24]
Amantadine DMS3YE9 Moderate Additive anticholinergic effects by the combination of Protriptyline and Amantadine. Influenza [1E30-1E32] [71]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Protriptyline caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [72]
Propiomazine DMKY8V1 Moderate Increased plasma concentrations of Protriptyline and Propiomazine due to competitive inhibition of the same metabolic pathway. Insomnia [7A00-7A0Z] [40]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Protriptyline and ITI-007. Insomnia [7A00-7A0Z] [24]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Protriptyline and Polyethylene glycol. Irritable bowel syndrome [DD91] [31]
Clidinium DMUMQZ0 Moderate Additive anticholinergic effects by the combination of Protriptyline and Clidinium. Irritable bowel syndrome [DD91] [24]
Dicyclomine DMZSDGX Moderate Additive anticholinergic effects by the combination of Protriptyline and Dicyclomine. Irritable bowel syndrome [DD91] [24]
Physostigmine DM2N0TO Moderate Antagonize the effect of Protriptyline when combined with Physostigmine. Lips/oral mucosa miscellaneous disorder [DA02] [36]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Protriptyline caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [32]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Protriptyline and Crizotinib. Lung cancer [2C25] [73]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Protriptyline and Porfimer Sodium. Lung cancer [2C25] [74]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Protriptyline and Ceritinib. Lung cancer [2C25] [31]
Dacomitinib DMOH8VY Moderate Decreased metabolism of Protriptyline caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [75]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Protriptyline and Osimertinib. Lung cancer [2C25] [76]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Protriptyline and Selpercatinib. Lung cancer [2C25] [32]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Protriptyline and Lumefantrine. Malaria [1F40-1F45] [37]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Protriptyline and Halofantrine. Malaria [1F40-1F45] [77]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Protriptyline and Chloroquine. Malaria [1F40-1F45] [78]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Protriptyline and Hydroxychloroquine. Malaria [1F40-1F45] [78]
Quinine DMSWYF5 Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Quinine. Malaria [1F40-1F45] [31]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Primaquine. Malaria [1F40-1F45] [31]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [32]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Protriptyline and Vemurafenib. Melanoma [2C30] [31]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Protriptyline and LGX818. Melanoma [2C30] [79]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Protriptyline and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [80]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Protriptyline and Flibanserin. Mood disorder [6A60-6E23] [81]
Doxylamine DMKOXFE Moderate Additive anticholinergic effects by the combination of Protriptyline and Doxylamine. Morning sickness disorder [SC00] [24]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Protriptyline and Panobinostat. Multiple myeloma [2A83] [82]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Protriptyline and Thalidomide. Multiple myeloma [2A83] [83]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Protriptyline and Fingolimod. Multiple sclerosis [8A40] [31]
Ozanimod DMT6AM2 Moderate Additive serotonergic effects by the combination of Protriptyline and Ozanimod. Multiple sclerosis [8A40] [84]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Romidepsin. Mycosis fungoides [2B01] [31]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Protriptyline caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [32]
Imatinib DM7RJXL Moderate Decreased metabolism of Protriptyline caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [85]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Dasatinib. Myeloproliferative neoplasm [2A20] [86]
Droperidol DM0DXA8 Major Increased risk of prolong QT interval by the combination of Protriptyline and Droperidol. Nausea/vomiting [MD90] [31]
Dimenhydrinate DM264B3 Moderate Additive anticholinergic effects by the combination of Protriptyline and Dimenhydrinate. Nausea/vomiting [MD90] [24]
Prochlorperazine DM53SRA Moderate Increased plasma concentrations of Protriptyline and Prochlorperazine due to competitive inhibition of the same metabolic pathway. Nausea/vomiting [MD90] [40]
Rolapitant DM8XP26 Moderate Decreased metabolism of Protriptyline caused by Rolapitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [87]
Cyclizine DM9G7BS Moderate Additive anticholinergic effects by the combination of Protriptyline and Cyclizine. Nausea/vomiting [MD90] [24]
Palonosetron DMBHMOX Major Additive serotonergic effects by the combination of Protriptyline and Palonosetron. Nausea/vomiting [MD90] [31]
Granisetron DMIUW25 Major Increased risk of prolong QT interval by the combination of Protriptyline and Granisetron. Nausea/vomiting [MD90] [31]
Dolasetron DMMG26Z Major Additive serotonergic effects by the combination of Protriptyline and Dolasetron. Nausea/vomiting [MD90] [31]
Ondansetron DMOTQ1I Major Additive serotonergic effects by the combination of Protriptyline and Ondansetron. Nausea/vomiting [MD90] [31]
Thiethylperazine DMU3IET Moderate Increased plasma concentrations of Protriptyline and Thiethylperazine due to competitive inhibition of the same metabolic pathway. Nausea/vomiting [MD90] [40]
Bupropion DM5PCS7 Major Decreased metabolism of Protriptyline caused by Bupropion mediated inhibition of CYP450 enzyme. Nicotine use disorder [6C4A] [31]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Entrectinib. Non-small cell lung cancer [2C25] [37]
Sibutramine DMFJTDI Major Additive serotonergic effects by the combination of Protriptyline and Sibutramine. Obesity [5B80-5B81] [88]
Lorcaserin DMG6OYJ Major Additive serotonergic effects by the combination of Protriptyline and Lorcaserin. Obesity [5B80-5B81] [89]
Dexfenfluramine DMJ7YDS Major Additive serotonergic effects by the combination of Protriptyline and Dexfenfluramine. Obesity [5B80-5B81] [25]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Protriptyline and Levomethadyl Acetate. Opioid use disorder [6C43] [32]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Lofexidine. Opioid use disorder [6C43] [32]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Protriptyline and Apraclonidine. Optic nerve disorder [9C40] [90]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Rucaparib. Ovarian cancer [2C73] [31]
Altretamine DMKLAYG Moderate Additive hypotensive effects by the combination of Protriptyline and Altretamine. Ovarian cancer [2C73] [91]
Pentazocine DM1XBHS Moderate Additive CNS depression effects by the combination of Protriptyline and Pentazocine. Pain [MG30-MG3Z] [34]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Protriptyline and Dextropropoxyphene. Pain [MG30-MG3Z] [92]
Butorphanol DM5KYPJ Moderate Additive serotonergic effects by the combination of Protriptyline and Butorphanol. Pain [MG30-MG3Z] [34]
Oxymorphone DM65AGJ Moderate Additive serotonergic effects by the combination of Protriptyline and Oxymorphone. Pain [MG30-MG3Z] [34]
Levorphanol DMGS80V Moderate Additive serotonergic effects by the combination of Protriptyline and Levorphanol. Pain [MG30-MG3Z] [34]
Flavoxate DMKV4NL Moderate Additive anticholinergic effects by the combination of Protriptyline and Flavoxate. Pain [MG30-MG3Z] [24]
Nalbuphine DMOSQGU Moderate Additive serotonergic effects by the combination of Protriptyline and Nalbuphine. Pain [MG30-MG3Z] [34]
Buprenorphine DMPRI8G Moderate Additive serotonergic effects by the combination of Protriptyline and Buprenorphine. Pain [MG30-MG3Z] [34]
Hydrocodone DMQ2JO5 Moderate Additive serotonergic effects by the combination of Protriptyline and Hydrocodone. Pain [MG30-MG3Z] [34]
Meperidine DMX4GND Major Additive serotonergic effects by the combination of Protriptyline and Meperidine. Pain [MG30-MG3Z] [25]
Oxycodone DMXLKHV Moderate Additive serotonergic effects by the combination of Protriptyline and Oxycodone. Pain [MG30-MG3Z] [34]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Triclabendazole. Parasitic worm infestation [1F90] [31]
Safinamide DM0YWJC Major Additive serotonergic effects by the combination of Protriptyline and Safinamide. Parkinsonism [8A00] [84]
Rasagiline DM3WKQ4 Major Additive serotonergic effects by the combination of Protriptyline and Rasagiline. Parkinsonism [8A00] [28]
Biperiden DME78OA Moderate Additive anticholinergic effects by the combination of Protriptyline and Biperiden. Parkinsonism [8A00] [24]
Procyclidine DMHFJDT Moderate Additive anticholinergic effects by the combination of Protriptyline and Procyclidine. Parkinsonism [8A00] [24]
Levodopa DMN3E57 Minor Altered absorption of Protriptyline due to GI dynamics variation caused by Levodopa. Parkinsonism [8A00] [93]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Pimavanserin. Parkinsonism [8A00] [94]
Orphenadrine DMW542E Moderate Additive anticholinergic effects by the combination of Protriptyline and Orphenadrine. Parkinsonism [8A00] [24]
Apomorphine DMX38HQ Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Apomorphine. Parkinsonism [8A00] [31]
Lindane DMB8CNL Moderate Increased risk of lowers seizure threshold by the combination of Protriptyline and Lindane. Pediculosis [1G00] [95]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Protriptyline and Methylscopolamine. Peptic ulcer [DA61] [24]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Protriptyline and Macimorelin. Pituitary gland disorder [5A60-5A61] [96]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Protriptyline and Lefamulin. Pneumonia [CA40] [97]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Degarelix. Prostate cancer [2C82] [32]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Protriptyline caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [98]
Nilutamide DMFN07X Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Nilutamide. Prostate cancer [2C82] [32]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Enzalutamide. Prostate cancer [2C82] [32]
Flutamide DMK0O7U Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Flutamide. Prostate cancer [2C82] [32]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Relugolix. Prostate cancer [2C82] [32]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Bicalutamide. Prostate cancer [2C82] [32]
Alfuzosin DMZVMKF Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Alfuzosin. Prostate hyperplasia [GA90] [31]
Levomepromazine DMIKFEL Moderate Increased plasma concentrations of Protriptyline and Levomepromazine due to competitive inhibition of the same metabolic pathway. Psychotic disorder [6A20-6A25] [40]
Fluphenazine DMIT8LX Moderate Increased plasma concentrations of Protriptyline and Fluphenazine due to competitive inhibition of the same metabolic pathway. Psychotic disorder [6A20-6A25] [40]
Triflupromazine DMKFQJP Moderate Increased plasma concentrations of Protriptyline and Triflupromazine due to competitive inhibition of the same metabolic pathway. Psychotic disorder [6A20-6A25] [40]
Sorafenib DMS8IFC Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Sorafenib. Renal cell carcinoma [2C90] [31]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Protriptyline and Gatifloxacin. Respiratory infection [CA07-CA4Z] [99]
Celecoxib DM6LOQU Moderate Decreased metabolism of Protriptyline caused by Celecoxib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [100]
Cyproheptadine DM92AH3 Moderate Additive anticholinergic effects by the combination of Protriptyline and Cyproheptadine. Rheumatoid arthritis [FA20] [24]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Quetiapine. Schizophrenia [6A20] [31]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Protriptyline and Mesoridazine. Schizophrenia [6A20] [31]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Protriptyline and Thioridazine. Schizophrenia [6A20] [101]
Aripiprazole DM3NUMH Moderate Additive anticholinergic effects by the combination of Protriptyline and Aripiprazole. Schizophrenia [6A20] [24]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Protriptyline and Iloperidone. Schizophrenia [6A20] [31]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Paliperidone. Schizophrenia [6A20] [31]
Loxapine DM8AI9U Moderate Additive anticholinergic effects by the combination of Protriptyline and Loxapine. Schizophrenia [6A20] [24]
Haloperidol DM96SE0 Major Decreased metabolism of Protriptyline caused by Haloperidol mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [102]
Perphenazine DMA4MRX Moderate Increased plasma concentrations of Protriptyline and Perphenazine due to competitive inhibition of the same metabolic pathway. Schizophrenia [6A20] [40]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Protriptyline and Molindone. Schizophrenia [6A20] [24]
Chlorpromazine DMBGZI3 Moderate Increased plasma concentrations of Protriptyline and Chlorpromazine due to competitive inhibition of the same metabolic pathway. Schizophrenia [6A20] [40]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Protriptyline and Thiothixene. Schizophrenia [6A20] [24]
Trifluoperazine DMKBYWI Moderate Increased plasma concentrations of Protriptyline and Trifluoperazine due to competitive inhibition of the same metabolic pathway. Schizophrenia [6A20] [40]
Risperidone DMN6DXL Moderate Additive anticholinergic effects by the combination of Protriptyline and Risperidone. Schizophrenia [6A20] [24]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Protriptyline and Amisulpride. Schizophrenia [6A20] [103]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Asenapine. Schizophrenia [6A20] [31]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Protriptyline and Pimozide. Schizophrenia [6A20] [32]
Fentanyl DM8WAHT Major Additive serotonergic effects by the combination of Protriptyline and Fentanyl. Sensation disturbance [MB40] [25]
Sufentanil DMU7YEL Moderate Additive CNS depression effects by the combination of Protriptyline and Sufentanil. Sensation disturbance [MB40] [34]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Vardenafil. Sexual dysfunction [HA00-HA01] [31]
Armodafinil DMGB035 Moderate Decreased metabolism of Protriptyline caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [37]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Protriptyline and LEE011. Solid tumour/cancer [2A00-2F9Z] [31]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Protriptyline and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [31]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [32]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [31]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [31]
Adenosine DMM2NSK Moderate Increased risk of ventricular arrhythmias by the combination of Protriptyline and Adenosine. Supraventricular tachyarrhythmia [BC81] [31]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Lenvatinib. Thyroid cancer [2D10] [31]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Protriptyline and Cabozantinib. Thyroid cancer [2D10] [32]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Protriptyline and Papaverine. Tonus and reflex abnormality [MB47] [104]
Tizanidine DMR2IQ4 Moderate Additive CNS depression effects by the combination of Protriptyline and Tizanidine. Tonus and reflex abnormality [MB47] [105]
Tacrolimus DMZ7XNQ Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Tacrolimus. Transplant rejection [NE84] [31]
Atropine DMEN6X7 Moderate Additive anticholinergic effects by the combination of Protriptyline and Atropine. Unspecific substance harmful effect [NE6Z] [24]
Astemizole DM2HN6Q Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Astemizole. Vasomotor/allergic rhinitis [CA08] [31]
Chlorpheniramine DM5URA2 Moderate Additive anticholinergic effects by the combination of Protriptyline and Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [24]
Triprolidine DM7SWIA Moderate Additive anticholinergic effects by the combination of Protriptyline and Triprolidine. Vasomotor/allergic rhinitis [CA08] [24]
Methdilazine DMAUHQX Moderate Increased plasma concentrations of Protriptyline and Methdilazine due to competitive inhibition of the same metabolic pathway. Vasomotor/allergic rhinitis [CA08] [40]
Carbinoxamine DMCT31R Moderate Additive anticholinergic effects by the combination of Protriptyline and Carbinoxamine. Vasomotor/allergic rhinitis [CA08] [24]
Brompheniramine DMFOVSD Moderate Additive anticholinergic effects by the combination of Protriptyline and Brompheniramine. Vasomotor/allergic rhinitis [CA08] [24]
Dexbrompheniramine DMKVWGE Moderate Additive anticholinergic effects by the combination of Protriptyline and Dexbrompheniramine. Vasomotor/allergic rhinitis [CA08] [24]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Protriptyline and Acrivastine. Vasomotor/allergic rhinitis [CA08] [24]
Azatadine DMZ80SB Moderate Additive anticholinergic effects by the combination of Protriptyline and Azatadine. Vasomotor/allergic rhinitis [CA08] [24]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Protriptyline and Procainamide. Ventricular tachyarrhythmia [BC71] [31]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Protriptyline and Propafenone. Ventricular tachyarrhythmia [BC71] [106]
Flecainide DMSQDLE Moderate Decreased metabolism of Protriptyline caused by Flecainide mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [106]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Protriptyline and Amiodarone. Ventricular tachyarrhythmia [BC71] [31]
⏷ Show the Full List of 246 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Quinoline yellow WS E00309 24671 Colorant
Sunset yellow FCF E00255 17730 Colorant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Calcium hydrogenphosphate E00294 24441 Diluent
Crospovidone E00626 Not Available Disintegrant
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 20 E00664 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
⏷ Show the Full List of 20 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Protriptyline 10 mg tablet 10 mg Oral Tablet Oral
Protriptyline 5 mg tablet 5 mg Oral Tablet Oral
Protriptyline Hydrochloride 5mg tablet 5mg Tablet Oral
Protriptyline Hydrochloride 10mg tablet 10mg Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7285).
2 Emerging treatments for depression. Expert Opin Pharmacother. 2006 Dec;7(17):2323-39.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 BDDCS applied to over 900 drugs
5 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Analgesic properties of intrathecally administered heterocyclic antidepressants. Pain. 1987 Mar;28(3):343-55.
8 Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.
9 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
10 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
11 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
12 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
13 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
14 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
15 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
16 Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
17 Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
18 Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8.
19 Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
20 Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
21 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
22 Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90.
23 Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
24 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
25 Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
26 Aranow AB, Hudson JI, Pope HG, et al "Elevated antidepressant plasma levels after addition of fluoxetine." Am J Psychiatry 146 (1989): 911-3. [PMID: 2787124]
27 Albers LJ, Reist C, Helmeste D, Vu R, Tang SW "Paroxetine shifts imipramine metabolism." Psychiatry Res 59 (1996): 189-96. [PMID: 8930024]
28 Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
29 Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6. [PMID: 9562139]
30 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
31 Canadian Pharmacists Association.
32 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
33 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
34 Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
35 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
36 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
37 Cerner Multum, Inc. "Australian Product Information.".
38 Hollingshead LM, Faulds D, Fitton A "Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris." Drugs 44 (1992): 835-57. [PMID: 1280569]
39 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
40 Bock JL, Nelson JC, Gray S, Jatlow PI "Desipramine hydroxylation: variability and effect of antipsychotic drugs." Clin Pharmacol Ther 33 (1983): 322-8. [PMID: 6130865]
41 Burke MS, Josephson A, Lightsey A "Combined methylphenidate and imipramine complication." J Am Acad Child Adolesc Psychiatry 34 (1995): 403-4. [PMID: 7751253]
42 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
43 Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61. [PMID: 15827071]
44 Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
45 Multum Information Services, Inc. Expert Review Panel.
46 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
47 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
48 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
49 Edelbroek PM, Zitman FG, Knoppert-van der Klein EA, van Putten PM, de Wolff FA "Therapeutic drug monitoring of amitriptyline: impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women." Clin Chim Acta 165 (1987): 177-87. [PMID: 3652444]
50 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
51 Ciraulo DA, Alderson LM, Chapron DJ, Jaffe JH, Subbarao B, Kramer PA "Imipramine disposition in alcoholics." J Clin Psychopharmacol 2 (1982): 2-7. [PMID: 7068940]
52 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
53 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
54 Fogelson DL "Fenfluramine and the cytochrome P450 system." Am J Psychiatry 154 (1997): 436-7. [PMID: 9054800]
55 Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
56 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
57 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
58 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
59 Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
60 AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
61 Abernethy DR, Greenblatt DJ, Shader RI "Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability." J Pharmacol Exp Ther 229 (1984): 702-5. [PMID: 6726654]
62 Gram LF, Kofod B, Christiansen J, Rafaelsen OJ "Imipramine metabolism: pH-dependent distribution and urinary excretion." Clin Pharmacol Ther 12 (1971): 239-44. [PMID: 5554940]
63 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
64 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
65 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
66 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
67 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
68 Eap CB, Bender S, Gastpar M, et al "Steady state plasma levels of the enantiomers of trimipramine and its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients." Ther Drug Monit 22 (2000): 209-14. [PMID: 10774635]
69 Product Information. Norvir (ritonavir). Abbott Pharmaceutical, Abbott Park, IL.
70 Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
71 Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
72 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
73 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
74 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
75 Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
76 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
77 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
78 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
79 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
80 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
81 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
82 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
83 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
84 Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
85 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
86 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
87 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
88 Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
89 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
90 Product Information. Iopidine (apraclonidine). Alcon Laboratories Inc, Fort Worth, TX.
91 Bruckner HW, Schleifer SJ "Orthostatic hypotension as a complication of hexamethylmelamine antidepressant interaction." Cancer Treat Rep 67 (1983): 516. [PMID: 6406063]
92 Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4. [PMID: 7103282]
93 Morgan JP, Rivera-Calimlim L, Messiha F, Sundaresan PR, Trabert N "Imipramine-mediated interference with levodopa absorption from the gastrointestinal tract in man." Neurology 25 (1975): 1029-34. [PMID: 1237820]
94 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
95 Matsuoka LY "Convulsions following application of gamma benzene hexachloride." J Am Acad Dermatol 5 (1981): 98-9. [PMID: 6168673]
96 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
97 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
98 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
99 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
100 Product Information. Celebrex (celecoxib). Searle, Chicago, IL.
101 Bluhm RE, Wilkinson GR, Shelton R, Branch RA "Genetically determined drug-metabolizing activity and desipramine- associated cardiotoxicity: a case report." Clin Pharmacol Ther 53 (1993): 89-95. [PMID: 8422746]
102 Alter P, Tontsch D, Grimm W "Doxepin-induced torsade de pointes tachycardia." Ann Intern Med 135 (2001): 384-5. [PMID: 11529713]
103 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
104 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
105 Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.
106 Katz MR "Raised serum levels of desipramine with the antiarrhythmic propafenone ." J Clin Psychiatry 52 (1991): 432-3. [PMID: 1938981]